We’re always looking to share how reputable organizations navigate conflicted sponsorship.
The latest example: Cochrane policy on commercial sponsorship of Cochrane Reviews and Cochrane Groups.
* “The intent of this policy is to ensure the independence of Cochrane Reviews by making sure there is no bias associated with commercial conflicts of interest in the conduct of Cochrane Reviews.”
* “Cochrane Reviews cannot be funded or conducted by commercial sponsors or commercial sources with a real or potential vested interest in the findings of a specific review.”
* “Individuals who are currently employed or where employed any time in the last three years by a company that has a real or potential financial interest in the outcome of the review (including but not limited to drug companies or medical device manufacturers); or who hold or have applied for a patent related to the review are prohibited from being Cochrane Review authors.”
* “Authors who in the last three years have received financial support from commercial sponsors or sources who have a real or potential financial interest in the findings of the review, but who are not covered by the restriction above should declare these interests at the earliest possible stage in the editorial process. Such financial support may include remuneration from a consultancy, grants, fees, fellowships, support for sabbaticals, royalties, stocks from pharmaceutical companies, advisory board membership, or otherwise.”
* “Editors with conflicts of interest with a given product/drug/non-drug intervention should not undertake peer review or be a contact editor, or provide sign-off on a review that involves that product, drug, non-drug intervention, or a competing intervention.”